Abstract
Background & Aims: Whether preoperative treatment of inflammatory bowel disease (IBD) with tumor necrosis factor inhibitors (TNFis) increases the risk of postoperative infectious complications remains controversial. The primary aim of this study was to determine whether preoperative exposure to TNFis is an independent risk factor for postoperative infectious complications within 30 days of surgery. Methods: We conducted a multicenter prospective observational study of patients with IBD undergoing intra-abdominal surgery across 17 sites from the Crohn's & Colitis Foundation Clinical Research Alliance. Infectious complications were categorized as surgical site infections (SSIs) or non-SSIs. Current TNFi exposure was defined as use within 12 weeks of surgery, and serum was collected for drug-level analyses. Multivariable models for occurrence of the primary outcome, any infection, or SSI were adjusted by predefined covariates (age, sex, preoperative steroid use, and disease type), baseline variables significantly associated (P < .05) with any infection or SSI separately, and TNFi exposure status. Exploratory models used TNFi exposure based on serum drug concentration. Results: A total of 947 patients were enrolled from September 2014 through June 2017. Current TNFi exposure was reported by 382 patients. Any infection (18.1% vs 20.2%, P = .469) and SSI (12.0% vs 12.6%, P = .889) rates were similar in patients currently exposed to TNFis and those unexposed. In multivariable analysis, current TNFi exposure was not associated with any infection (odds ratio, 1.050; 95% confidence interval, 0.716–1.535) or SSI (odds ratio, 1.249; 95% confidence interval, 0.793–1.960). Detectable TNFi drug concentration was not associated with any infection or SSI. Conclusions: Preoperative TNFi exposure was not associated with postoperative infectious complications in a large prospective multicenter cohort.
Original language | English (US) |
---|---|
Pages (from-to) | 204-221 |
Number of pages | 18 |
Journal | Gastroenterology |
Volume | 163 |
Issue number | 1 |
DOIs | |
State | Published - Jul 2022 |
Keywords
- Crohn's Disease
- Infection
- Surgery
- Tumor Necrosis Factor Inhibitor
- Ulcerative Colitis
ASJC Scopus subject areas
- Hepatology
- Gastroenterology
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Prospective Cohort Study to Investigate the Safety of Preoperative Tumor Necrosis Factor Inhibitor Exposure in Patients With Inflammatory Bowel Disease Undergoing Intra-abdominal Surgery'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Prospective Cohort Study to Investigate the Safety of Preoperative Tumor Necrosis Factor Inhibitor Exposure in Patients With Inflammatory Bowel Disease Undergoing Intra-abdominal Surgery. / Cohen, Benjamin L.; Fleshner, Phillip; Kane, Sunanda V. et al.
In: Gastroenterology, Vol. 163, No. 1, 07.2022, p. 204-221.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Prospective Cohort Study to Investigate the Safety of Preoperative Tumor Necrosis Factor Inhibitor Exposure in Patients With Inflammatory Bowel Disease Undergoing Intra-abdominal Surgery
AU - Cohen, Benjamin L.
AU - Fleshner, Phillip
AU - Kane, Sunanda V.
AU - Herfarth, Hans H.
AU - Palekar, Nicole
AU - Farraye, Francis A.
AU - Leighton, Jonathan A.
AU - Katz, Jeffry A.
AU - Cohen, Russell D.
AU - Gerich, Mark E.
AU - Cross, Raymond K.
AU - Higgins, Peter D.R.
AU - Tinsley, Andrew
AU - Glover, Sarah
AU - Siegel, Corey A.
AU - Bohl, Jaime L.
AU - Iskandar, Heba
AU - Ji, Jiayi
AU - Hu, Liangyuan
AU - Sands, Bruce E.
N1 - Funding Information: Funding Bruce E. Sands received funding support from the Crohn’s & Colitis Foundation Senior Research Award (GCO# 12-0899, Foundation Ref #276439). The funding sponsor (Crohn’s & Colitis Foundation) was not involved in the study design in the collection, analysis, and interpretation of data Funding Information: The authors thank Prometheus Laboratories Inc (San Diego, CA) for performing the serum drug level analyses. The authors thank Judith Harjes, Samantha Raymond, Ruiqi Huang, and Mayte Suarez-Farinas for assistance with database maintenance and initial statistical analyses and thank Josephine Mitcham for central coordination. Benjamin L Cohen, MD, MAS (Conceptualization: Lead; Data curation: Lead; Formal analysis: Lead; Funding acquisition: Lead; Investigation: Lead; Methodology: Lead; Project administration: Lead; Supervision: Lead; Validation: Lead; Visualization: Lead; Writing – original draft: Lead; Writing – review & editing: Lead). Phillip Fleshner, MD (Investigation: Supporting; Writing – original draft: Supporting; Writing – review & editing: Supporting). Sunanda V. Kane, MD (Investigation: Supporting; Writing – original draft: Supporting; Writing – review & editing: Supporting). Hans H. Herfarth, MD (Conceptualization: Supporting; Investigation: Supporting; Writing – review & editing: Supporting). Nicole Palekar, MD (Investigation: Supporting; Writing – review & editing: Supporting). Francis A. Farraye, MD (Investigation: Supporting; Writing – review & editing: Supporting). Jonathan A. Leighton, MD (Investigation: Supporting; Writing – review & editing: Supporting). Jeffry A. Katz, MD (Investigation: Supporting; Writing – review & editing: Supporting). Russell D. Cohen, MD (Investigation: Supporting; Writing – review & editing: Supporting). Mark E. Gerich, MD (Investigation: Supporting; Writing – review & editing: Supporting). Raymond K. Cross, MD (Investigation: Supporting; Writing – review & editing: Supporting). Peter D.R. Higgins, MD (Conceptualization: Supporting; Investigation: Supporting; Writing – review & editing: Supporting). Andrew Tinsley, MD (Investigation: Supporting; Writing – review & editing: Supporting). Sarah Glover, DO (Investigation: Supporting; Writing – review & editing: Supporting). Corey A. Siegel, MD (Investigation: Supporting; Writing – review & editing: Supporting). Jaime L. Bohl, MD (Investigation: Supporting; Writing – review & editing: Supporting). Heba Iskandar, MD (Investigation: Supporting; Writing – review & editing: Supporting). Jiayi Ji, MD, MS (Data curation: Lead; Formal analysis: Lead; Methodology: Supporting; Writing – original draft: Supporting; Writing – review & editing: Supporting). Liangyuan Hu, PhD (Data curation: Lead; Formal analysis: Lead; Methodology: Supporting; Writing – original draft: Supporting; Writing – review & editing: Supporting). Bruce E. Sands, MD, MS (Conceptualization: Lead; Data curation: Lead; Formal analysis: Lead; Funding acquisition: Lead; Investigation: Lead; Methodology: Lead; Project administration: Lead; Resources: Lead; Supervision: Lead; Validation: Lead; Visualization: Lead; Writing – original draft: Lead; Writing – review & editing: Lead). Conflicts of interest The authors disclose the following: Benjamin L. Cohen reports personal fees from AbbVie, Celgene–Bristol-Myers Squibb, Sublimity Therapeutics, Target RWE, Janssen, Ferring, AlphaSigma, and Takeda, and personal fees and nonfinancial support from Pfizer, outside the submitted work. Phillip Fleshner reports consulting fees from Takeda. Sunanda V. Kane discloses personal fees as a consultant to Bristol-Myers Squibb, Gilead, InveniAI, Janssen, Kinetix Health, Seres Therapeutics, Spherix Health, TechLab, and United Health Group, and serves as the Editor of the IBD Section of UptoDate. Hans H. Herfarth discloses research grants from Allakos, Artizan, Novo Nordisk, and Pfizer, and consulting fees from Alivio, Bristol-Myers Squibb, Boehringer, ExeGi Pharma, Finch, Gilead, Janssen, Pfizer, Pure Tech, and Otsuka. Nicole Palekar discloses speaking for AbbVie. Francis A. Farraye discloses personal fees as a consultant to Arena, Bristol-Myers Squibb, Braintree Labs, Gilead, GI Reviewers, GSK, IBD Educational Group, Iterative Scopes, Janssen, Pfizer, and Sebela, stock ownership of Innovation Pharmaceuticals, and serves on the Data and Safety Monitoring Boards for Lilly and Theravance. Jonathan A. Leighton reports research support from Alimentiv and Takeda. Raymond K. Cross has received income from consulting and participation in advisory boards for AbbVie, Bristol-Myers Squibb, Eli Lilly, Janssen, Pfizer, Samsung Bioepis, and Takeda. Peter D.R. Higgins received consulting fees from AbbVie and Eli Lilly, and speaking honoraria from Imedex and Vindico. Andrew Tinsley discloses speaking for AbbVie and Bristol-Myers Squibb. Corey A. Siegel discloses personal fees as a consultant to AbbVie, Bristol-Myers Squibb, Lilly, Janssen, Pfizer, Prometheus, Takeda, and Trellus Health, and is a speaker for Continuing Medical Education activities sponsored by AbbVie, Janssen, Pfizer, and Takeda. Corey A. Siegel discloses grant support from AbbVie, Janssen, Pfizer, and Takeda, and equity interest as a cofounder of MiTest Health, LLC (software company). Technology developed by MiTest Health, LLC has been licensed to Takeda. Heba Iskandar discloses research grants as site primary investigator from AbbVie, Janssen, Celgene, Bristol-Myers Squibb, Boehringer, Takeda, and UCB, and consulting fees from Bristol-Myers Squibb, Boehringer, and AbbVie. Bruce E. Sands discloses research grants from Takeda, Pfizer, Theravance Biopharma R&D, and Janssen, consulting fees from 4D Pharma, Abivax, AbbVie, Alimentiv, Allergan, Amgen, Arena Pharmaceuticals, AstraZeneca, Bacainn Therapeutics, Boehringer-Ingelheim, Boston Pharmaceuticals, Bristol-Myers Squibb, Calibr, Capella Bioscience, Celgene, Celltrion Healthcare, ClostraBio, Enthera, F. Hoffmann-La Roche, Ferring, Galapagos, Gilead, GSK, GossamerBio, Immunic, Index Pharmaceuticals, Innovation Pharmaceuticals, Ironwood Pharmaceuticals, Janssen, Kaleido, Kallyope, Lilly, MiroBio, Morphic Therapeutic, Oppilan Pharma, OSE Immunotherapeutics, Otsuka, Palatin Technologies, Pfizer, Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonist Therapeutics, Q32 Bio, Redhill Biopharma, Rheos Medicines, Salix Pharmaceuticals, Seres Therapeutics, Shire, Sienna Biopharmaceuticals, Sun Pharma, Surrozen, Takeda, Target PharmaSolutions, Teva Branded Pharmaceutical Products R&D, Thelium, Theravance Biopharma R&D, TLL Pharma, USWM Enterprises, Ventyx Biosciences, Viela Bio, Vivante Health, and Vivelix Pharmaceuticals, and stock for Vivante Health and Ventyx Biosciences. The other authors disclose no conflicts. Funding Bruce E. Sands received funding support from the Crohn's & Colitis Foundation Senior Research Award (GCO# 12-0899, Foundation Ref #276439). The funding sponsor (Crohn's & Colitis Foundation) was not involved in the study design in the collection, analysis, and interpretation of data Publisher Copyright: © 2022 AGA Institute
PY - 2022/7
Y1 - 2022/7
N2 - Background & Aims: Whether preoperative treatment of inflammatory bowel disease (IBD) with tumor necrosis factor inhibitors (TNFis) increases the risk of postoperative infectious complications remains controversial. The primary aim of this study was to determine whether preoperative exposure to TNFis is an independent risk factor for postoperative infectious complications within 30 days of surgery. Methods: We conducted a multicenter prospective observational study of patients with IBD undergoing intra-abdominal surgery across 17 sites from the Crohn's & Colitis Foundation Clinical Research Alliance. Infectious complications were categorized as surgical site infections (SSIs) or non-SSIs. Current TNFi exposure was defined as use within 12 weeks of surgery, and serum was collected for drug-level analyses. Multivariable models for occurrence of the primary outcome, any infection, or SSI were adjusted by predefined covariates (age, sex, preoperative steroid use, and disease type), baseline variables significantly associated (P < .05) with any infection or SSI separately, and TNFi exposure status. Exploratory models used TNFi exposure based on serum drug concentration. Results: A total of 947 patients were enrolled from September 2014 through June 2017. Current TNFi exposure was reported by 382 patients. Any infection (18.1% vs 20.2%, P = .469) and SSI (12.0% vs 12.6%, P = .889) rates were similar in patients currently exposed to TNFis and those unexposed. In multivariable analysis, current TNFi exposure was not associated with any infection (odds ratio, 1.050; 95% confidence interval, 0.716–1.535) or SSI (odds ratio, 1.249; 95% confidence interval, 0.793–1.960). Detectable TNFi drug concentration was not associated with any infection or SSI. Conclusions: Preoperative TNFi exposure was not associated with postoperative infectious complications in a large prospective multicenter cohort.
AB - Background & Aims: Whether preoperative treatment of inflammatory bowel disease (IBD) with tumor necrosis factor inhibitors (TNFis) increases the risk of postoperative infectious complications remains controversial. The primary aim of this study was to determine whether preoperative exposure to TNFis is an independent risk factor for postoperative infectious complications within 30 days of surgery. Methods: We conducted a multicenter prospective observational study of patients with IBD undergoing intra-abdominal surgery across 17 sites from the Crohn's & Colitis Foundation Clinical Research Alliance. Infectious complications were categorized as surgical site infections (SSIs) or non-SSIs. Current TNFi exposure was defined as use within 12 weeks of surgery, and serum was collected for drug-level analyses. Multivariable models for occurrence of the primary outcome, any infection, or SSI were adjusted by predefined covariates (age, sex, preoperative steroid use, and disease type), baseline variables significantly associated (P < .05) with any infection or SSI separately, and TNFi exposure status. Exploratory models used TNFi exposure based on serum drug concentration. Results: A total of 947 patients were enrolled from September 2014 through June 2017. Current TNFi exposure was reported by 382 patients. Any infection (18.1% vs 20.2%, P = .469) and SSI (12.0% vs 12.6%, P = .889) rates were similar in patients currently exposed to TNFis and those unexposed. In multivariable analysis, current TNFi exposure was not associated with any infection (odds ratio, 1.050; 95% confidence interval, 0.716–1.535) or SSI (odds ratio, 1.249; 95% confidence interval, 0.793–1.960). Detectable TNFi drug concentration was not associated with any infection or SSI. Conclusions: Preoperative TNFi exposure was not associated with postoperative infectious complications in a large prospective multicenter cohort.
KW - Crohn's Disease
KW - Infection
KW - Surgery
KW - Tumor Necrosis Factor Inhibitor
KW - Ulcerative Colitis
UR - http://www.scopus.com/inward/record.url?scp=85130399177&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85130399177&partnerID=8YFLogxK
U2 - 10.1053/j.gastro.2022.03.057
DO - 10.1053/j.gastro.2022.03.057
M3 - Article
C2 - 35413359
AN - SCOPUS:85130399177
SN - 0016-5085
VL - 163
SP - 204
EP - 221
JO - Gastroenterology
JF - Gastroenterology
IS - 1
ER -